EP3687540A4 - Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same - Google Patents

Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same Download PDF

Info

Publication number
EP3687540A4
EP3687540A4 EP18859565.6A EP18859565A EP3687540A4 EP 3687540 A4 EP3687540 A4 EP 3687540A4 EP 18859565 A EP18859565 A EP 18859565A EP 3687540 A4 EP3687540 A4 EP 3687540A4
Authority
EP
European Patent Office
Prior art keywords
composition
same
heteroaryl compounds
cxcr4 inhibitors
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859565.6A
Other languages
German (de)
French (fr)
Other versions
EP3687540A1 (en
Inventor
Xiaohu Zhang
Jiyue ZHENG
Haikuo MA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cgenetech Suzhou China Co Ltd
Original Assignee
Cgenetech Suzhou China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810265417.9A external-priority patent/CN110317191B/en
Priority claimed from CN201810710340.1A external-priority patent/CN110669036B/en
Priority claimed from CN201811034891.7A external-priority patent/CN109553604B/en
Application filed by Cgenetech Suzhou China Co Ltd filed Critical Cgenetech Suzhou China Co Ltd
Publication of EP3687540A1 publication Critical patent/EP3687540A1/en
Publication of EP3687540A4 publication Critical patent/EP3687540A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
EP18859565.6A 2017-09-25 2018-09-24 Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same Pending EP3687540A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710875041 2017-09-25
CN201810265417.9A CN110317191B (en) 2018-03-28 2018-03-28 Pyridine heterocyclic compound and application thereof as CXCR4 inhibitor
CN201810710340.1A CN110669036B (en) 2018-07-02 2018-07-02 Heterocyclic compounds with CXCR4 signal channel inhibition activity and application thereof
CN201811034891.7A CN109553604B (en) 2017-09-25 2018-09-05 4-aminopyrimidine derivatives as CXCR4 inhibitors and uses thereof
PCT/US2018/052503 WO2019060860A1 (en) 2017-09-25 2018-09-24 Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same

Publications (2)

Publication Number Publication Date
EP3687540A1 EP3687540A1 (en) 2020-08-05
EP3687540A4 true EP3687540A4 (en) 2021-04-21

Family

ID=65809950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859565.6A Pending EP3687540A4 (en) 2017-09-25 2018-09-24 Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same

Country Status (3)

Country Link
EP (1) EP3687540A4 (en)
KR (1) KR20200058443A (en)
WO (1) WO2019060860A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545814A (en) 2017-02-21 2019-12-06 爱默蕾大学 Chemokine CXCR4 receptor modulators and uses related thereto
WO2019183133A1 (en) 2018-03-19 2019-09-26 Emory University Pan-Tropic Entry Inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
WO2006076131A2 (en) * 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
CN102675305A (en) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 Imidazopyridine compounds, as well as preparation method and application thereof
CN103570683A (en) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 Multi-substituted amine compound, as well as preparation method and use thereof
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
SG189723A1 (en) * 2008-03-28 2013-05-31 Altiris Therapeutics Chemokine receptor modulators
WO2010025416A1 (en) * 2008-08-29 2010-03-04 Genzyme Corporation Cxcr4 antagonists for kidney injury
WO2017011517A1 (en) * 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
WO2006076131A2 (en) * 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
CN102675305A (en) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 Imidazopyridine compounds, as well as preparation method and application thereof
CN103570683A (en) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 Multi-substituted amine compound, as well as preparation method and use thereof
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019060860A1 *

Also Published As

Publication number Publication date
WO2019060860A1 (en) 2019-03-28
KR20200058443A (en) 2020-05-27
EP3687540A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
EP3665156A4 (en) Compounds, compositions and methods
EP3687540A4 (en) Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same
EP3676297A4 (en) Compounds, compositions and methods
EP3661966A4 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3677583A4 (en) Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
EP3424928A4 (en) Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
EP3599868A4 (en) Herbicidal mixture, composition and method
EP3580208A4 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EP3923935A4 (en) Compounds, compositions and methods
EP3594312A4 (en) Composition, method for producing same, and use thereof
EP3924341A4 (en) Compounds, compositions and methods
EP3345900A4 (en) 2, 4-di-(nitrogen containing group) substituted pyrimidine compound and preparation method and use thereof
EP3415502A4 (en) Substituted heteroaryl compound, composition containing same, and application thereof
IL286471A (en) Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component
EP3722395A4 (en) Friction-controlling compound, and friction-controlling composition containing said friction-controlling compound
EP3640248A4 (en) Aminopyrimidine compound, preparation method therefor and use thereof
EP3552017A4 (en) Compounds, compositions and methods
EP3908277A4 (en) Heteroaryl compounds as necrosis inhibitors, composition and method using the same
EP3626686A4 (en) Composition for glass, glass, preparation method and application thereof
EP3715342A4 (en) Fluorosulfonyl-containing compound, intermediate thereof, preparation method therefor and use thereof
EP3584298A4 (en) Polishing composition, method for producing same, and polishing method using polishing composition
EP3447054A4 (en) Compound and preparation method therefor, composition and application thereof
HRP20200104T8 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
EP3409709A4 (en) Photocuring method, compound and composition used therein
EP3670511A4 (en) Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210208BHEP

Ipc: A61P 11/00 20060101ALI20210208BHEP

Ipc: A61P 35/00 20060101ALI20210208BHEP

Ipc: C07D 401/14 20060101ALI20210208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210324

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210318BHEP

Ipc: C07D 401/14 20060101ALI20210318BHEP

Ipc: A61P 11/00 20060101ALI20210318BHEP

Ipc: A61P 35/00 20060101ALI20210318BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220802